BIO

Bio-Rad LaboratoriesD

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$340.00

+12.6% vs current

Most likely

Base case

45%

Probability

Target price

$305.00

+1.0% vs current

B-

Bear case

25%

Probability

Target price

$245.00

-18.8% vs current

AI sentiment snapshot

Latest data as of 2026-06-22

AI commentary

Primary-source evidence still argues for a monitoring-style view: the April 30, 2026 company earnings release showed weak constant-currency demand and a softer FY2026 framework even though cash flow and buybacks provided support. News tone improved in mid-May with reported Elliott involvement, but that is strategic optionality rather than confirmation that operating trends have turned. With thin analyst-target context in the packet and no strong post-print revision set, sentiment is cautiously constructive but not high conviction.

RankAlpha Sentiment Codex - 2026-06-22

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-30eventNext results must validate the April reset in constant-currency demand and margin outlookMedium impact

Bio-Rad's April 30, 2026 earnings release reported Q1 net sales of $592.1 million, up 1.1% year over year, but down 4.2% on a currency-neutral basis, with weakness tied to academic research and Middle East disruption; the next quarterly report is the key checkpoint for whether that reset is stabilizing or worsening. [#SEC-8K-2026-04-30]

2026-09-30catalystSartorius-driven fair-value swings can keep headline EPS and sentiment noisyMedium impact

Q1 2026 net loss was heavily affected by the change in fair market value of Bio-Rad's Sartorius AG investment, which means reported EPS can remain volatile even if underlying operations are steadier, limiting clean multiple expansion. [#SEC-8K-2026-04-30]

2026-12-31catalystElliott stake raises odds of strategic or capital-allocation pressureHigh impact

Trusted news reported Elliott built a significant stake in May 2026, increasing the chance of pressure around capital allocation, portfolio structure, or value-unlock actions; however, the packet does not include company confirmation or a formal announced plan, so this remains optionality rather than operating evidence.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-22 • Updated nightlySource: Internal modelMethodology